Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CRM
IHD
Cosentyx® - Anti IL-17
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04209205 INVIGORATE-2 (CAIN457P12302)
Psoriatic Arthritis (PSA)
Phase 3
380
The proportion of subjects achieving American College of Rheumatology 50
(ACR50) response criteria
Secukinumab intravenous (i.v.) regimen
Placebo intravenous (i.v.) regimen
Patients with active psoriatic arthritis (PSA) despite current or previous NSAID,
DMARD and/or anti-TNF therapy
Target Patients
Read-out Milesstone(s)
2022
Publication
2023
NCT04300296 PRELUDE (CAIN457S12201)
Lichen Planus
Phase 2
108
Proportion of patients achieving Investigator's Global Assessment (IGA 0/1) score
at 16 weeks +30% delta vs placebo
Secukinumab 300 mg s.c.
Placebo s.c.
Adult patients with biopsy-proven lichen planus not adequately controlled by topical
therapies
2022
TBD
79 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation